314 related articles for article (PubMed ID: 33081013)
1. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology.
Chung R; Tyebally S; Chen D; Kapil V; Walker JM; Addison D; Ismail-Khan R; Guha A; Ghosh AK
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081013
[TBL] [Abstract][Full Text] [Related]
2. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
3. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
[TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
5. Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients.
Vaitiekus D; Muckiene G; Vaitiekiene A; Maciuliene D; Vaiciuliene D; Ambrazeviciute G; Sereikaite L; Verikas D; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2020 Jun; 20(3):321-327. PubMed ID: 31782105
[TBL] [Abstract][Full Text] [Related]
6. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.
Rhea IB; Oliveira GH
Curr Treat Options Cardiovasc Med; 2018 Jun; 20(7):53. PubMed ID: 29922881
[TBL] [Abstract][Full Text] [Related]
9. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
11. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
12. Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
Tini G; Tocci G; Battistoni A; Sarocchi M; Pietrantoni C; Russo D; Musumeci B; Savoia C; Volpe M; Spallarossa P
Curr Heart Fail Rep; 2023 Feb; 20(1):56-62. PubMed ID: 36696001
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology.
Chen M; Xue J; Wang M; Yang J; Chen T
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297017
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Jin X; Bai Y; Gao L; Wu S
Cancer Chemother Pharmacol; 2019 Sep; 84(3):599-607. PubMed ID: 31203389
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Complications in the Adult Bone Marrow Transplant Patient.
Tuzovic M; Mead M; Young PA; Schiller G; Yang EH
Curr Oncol Rep; 2019 Mar; 21(3):28. PubMed ID: 30826891
[TBL] [Abstract][Full Text] [Related]
17. Hypertension in the Cardio-Oncology Clinic.
Hassen LJ; Lenihan DJ; Baliga RR
Heart Fail Clin; 2019 Oct; 15(4):487-495. PubMed ID: 31472884
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.
Ryan TD; Nagarajan R; Godown J
Curr Treat Options Oncol; 2019 May; 20(7):56. PubMed ID: 31129800
[TBL] [Abstract][Full Text] [Related]
19. Arterial hypertension in cancer: The elephant in the room.
Tini G; Sarocchi M; Tocci G; Arboscello E; Ghigliotti G; Novo G; Brunelli C; Lenihan D; Volpe M; Spallarossa P
Int J Cardiol; 2019 Apr; 281():133-139. PubMed ID: 30718135
[TBL] [Abstract][Full Text] [Related]
20. Management of Cancer Therapeutics-Related Cardiac Dysfunction.
Vallakati A; Konda B; Lenihan DJ; Baliga RR
Heart Fail Clin; 2018 Oct; 14(4):553-567. PubMed ID: 30266364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
